Raymond James & Associates lifted its position in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Free Report) by 8.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 91,380 shares of the company’s stock after acquiring an additional 7,146 shares during the period. Raymond James & Associates owned about 0.19% of C4 Therapeutics worth $170,000 at the end of the most recent reporting period.
Several other hedge funds have also modified their holdings of CCCC. Swiss National Bank lifted its holdings in shares of C4 Therapeutics by 7.9% during the first quarter. Swiss National Bank now owns 28,800 shares of the company’s stock valued at $699,000 after purchasing an additional 2,100 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of C4 Therapeutics by 141.7% during the 1st quarter. JPMorgan Chase & Co. now owns 69,420 shares of the company’s stock worth $1,684,000 after purchasing an additional 40,698 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of C4 Therapeutics by 1.3% during the 1st quarter. Bank of New York Mellon Corp now owns 127,072 shares of the company’s stock worth $3,083,000 after purchasing an additional 1,601 shares in the last quarter. MetLife Investment Management LLC raised its stake in shares of C4 Therapeutics by 58.5% during the 1st quarter. MetLife Investment Management LLC now owns 21,112 shares of the company’s stock worth $512,000 after purchasing an additional 7,792 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in shares of C4 Therapeutics by 6.3% during the 1st quarter. Rhumbline Advisers now owns 40,699 shares of the company’s stock worth $987,000 after purchasing an additional 2,423 shares in the last quarter. 74.88% of the stock is owned by hedge funds and other institutional investors.
C4 Therapeutics Price Performance
C4 Therapeutics stock opened at $5.51 on Thursday. C4 Therapeutics, Inc. has a one year low of $1.06 and a one year high of $8.42. The stock’s fifty day moving average price is $5.01 and its two-hundred day moving average price is $3.28. The firm has a market cap of $271.53 million, a PE ratio of -2.00 and a beta of 2.99.
Wall Street Analyst Weigh In
C4 Therapeutics Company Profile
C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma.
- Five stocks we like better than C4 Therapeutics
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- What are specialty REITs? How to invest in them
- Compound Interest and Why It Matters When Investing
- Miso Robotics stock: Is an IPO coming soon?
- What Does a Stock Split Mean?
- Insiders are selling these hot stocks on track for higher prices
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.